In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lilly/Daiichi Sankyo's Effient Will Be Constrained by the Widespread Use of Astrazeneca's Brilinta

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018 in the acute coronary syndrome drug market, the overall uptake of Eli Lilly/Daiichi Sankyo's Effient in the United States and Europe (where it is marketed as Efient) will be constrained by the widespread use of AstraZeneca's Brilinta, which is expected to launch in 2011.

The Pharmacor 2010 findings from the topic entitled Acute Coronary Syndrome reveals that Effient will likely find greatest use in patient subgroups such as ST-segment elevation myocardial infarction (STEMI) patients, diabetics and patients who are at high risk of stent thrombosis but at modest risk of bleeding. Following last year's launch of Effient, cardiologists now have the option of prescribing an adenosine diphosphate (ADP) receptor antagonist that is more potent than clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis's Plavix/Iscover, generics).

However, the drawbacks of Effient include a high rate of bleeding and lack of reversibility while other emerging agents in the ADP receptor antagonist class such as Brilinta and Novartis's elinogrel offer reversibility. As a result, Brilinta and elinogrel provide greater safety and flexibility in patients who need coronary artery bypass graft (CABG) surgery. Furthermore, Brilinta is supported by a compelling mortality benefit in recently reported data from the PLATO clinical trial.

"Brilinta and elinogrel all have potential advantages over both Effient and Plavix because they are reversible and do not require in vivo activation," said Decision Resources Therapeutic Area Director Nikhil Mehta. "Therefore, patients taking these agents can undergo surgery in a shorter amount of time. Additionally, Brilinta and elinogrel also have a more consistent effect and quicker onset of action than Plavix."

The Pharmacor 2010 findings also reveal that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

SOURCE Decision Resources

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED